DS
CYTK icon

David Shaw’s Cytokinetics CYTK Stock Holding History

David Shaw’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,700
Closed -$2.68M – 4932
2026
Q1 		$2.68M Sell
40,700
-40,800
-50% -$2.59M ﹤0.01% 2692
2025
Q4 		$5.18M Buy
81,500
+8,800
+12% +$547K ﹤0.01% 2268
2025
Q3 		$4M Sell
72,700
-8,900
-11% -$367K ﹤0.01% 2416
2025
Q2 		$2.7M Buy
81,600
+8,900
+12% +$310K ﹤0.01% 2516
2025
Q1 		$2.92M Sell
72,700
-11,600
-14% -$533K ﹤0.01% 2322
2024
Q4 		$3.97M Sell
84,300
-35,000
-29% -$1.82M ﹤0.01% 2165
2024
Q3 		$6.3M Hold
119,300
– – 0.01% 1775
2024
Q2 		$6.46M Buy
119,300
+55,000
+86% +$3.32M 0.01% 1654
2024
Q1 		$4.51M Buy
+64,300
New +$4.97M ﹤0.01% 1972

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's CYTK Position: Q2 2026 in Review

David Shaw increased its Cytokinetics (CYTK) stake by 48% in Q2 2026, buying an estimated $24.5M and bringing the position to 1,048,103 shares worth $89.3M. The position accounts for 0.04% of the portfolio, ranked #490.

David Shaw first reported a position in CYTK in Q3 2013 and has held it in 39 quarters since. 479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • David Shaw held 1,048,103 shares of Cytokinetics worth $89.3M as of Q2 2026.
  • David Shaw bought 341,472 Cytokinetics shares in Q2 2026, an estimated $24.5M.
  • Cytokinetics made up 0.04% of David Shaw's portfolio in Q2 2026, its #490 holding.
  • David Shaw first reported a position in Cytokinetics in Q3 2013 and has held it in 39 quarters since.
  • 479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.